The Company for Cooperative Insurance (8010) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
28 Jul, 2026Executive summary
Net profit after zakat for Q1 2026 reached SAR 288.6 million, up from SAR 261.7 million year-over-year.
Total comprehensive income for the period was SAR 288.6 million, with no significant items reclassified to income.
The Board recommended a 50% capital increase via bonus shares and a 20% cash dividend distribution.
Financial highlights
Insurance and reinsurance revenue rose to SAR 5.77 billion from SAR 5.12 billion year-over-year.
Net profit before zakat was SAR 322.5 million, compared to SAR 294.4 million in Q1 2025.
Basic earnings per share increased to SAR 1.93 from SAR 1.76 year-over-year.
Total assets grew to SAR 25.04 billion from SAR 21.76 billion at year-end 2025.
Gross written premiums for Q1 2026 were SAR 7.53 billion, up from SAR 6.55 billion in Q1 2025.
Outlook and guidance
The company is preparing for a transition to a Risk-Based Capital regime by 2027, aiming to enhance solvency and capital adequacy.
Management continues to monitor geopolitical risks and their potential impact on financial performance.
Latest events from The Company for Cooperative Insurance
- Net profit up 8% to 1.1 Bn, GWP up 20%, with strong growth across all core segments.8010
Q4 202528 Jul 2026 - Net profit after Zakat rose 66% to SAR 1,022 million, driven by growth and digital innovation.8010
Q4 202428 Jul 2026 - Net profit after zakat surged 105% year-over-year to SAR 656.5 million on strong revenue growth.8010
Q2 202428 Jul 2026 - Net profit after zakat surged to SAR 854 million on higher insurance revenue and strong segment growth.8010
Q3 202428 Jul 2026 - Net profit after zakat rose 33% to SAR 261.7 million, with strong insurance revenue growth.8010
Q1 202528 Jul 2026 - Net profit after zakat rose to SAR 729.1 million on SAR 10.35 billion revenue for H1 2025.8010
Q2 202528 Jul 2026 - Insurance revenue and net profit rose, supported by strong medical and P&C growth.8010
Q3 202528 Jul 2026